These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18800611)

  • 1. [Molecular targeted therapy for renal cell carcinoma].
    Kakehi Y
    Rinsho Ketsueki; 2008 Aug; 49(8):622-5. PubMed ID: 18800611
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal-cell carcinoma--molecular pathways and therapies.
    Brugarolas J
    N Engl J Med; 2007 Jan; 356(2):185-7. PubMed ID: 17215538
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
    Vira MA; Novakovic KR; Pinto PA; Linehan WM
    BJU Int; 2007 May; 99(5 Pt B):1223-9. PubMed ID: 17441915
    [No Abstract]   [Full Text] [Related]  

  • 4. Newly approved therapies for RCC and their effect on the standard of care.
    Figlin RA
    Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
    [No Abstract]   [Full Text] [Related]  

  • 5. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN; Flaherty KT
    Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract]   [Full Text] [Related]  

  • 7. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy for metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM
    J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting von Hippel-Lindau pathway in renal cell carcinoma.
    Patel PH; Chadalavada RS; Chaganti RS; Motzer RJ
    Clin Cancer Res; 2006 Dec; 12(24):7215-20. PubMed ID: 17189392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular basis of targeted therapy in metastatic renal cancer].
    Moch H
    Pathologe; 2008 Nov; 29 Suppl 2():184-6. PubMed ID: 18751979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
    Rini BI
    Curr Oncol Rep; 2006 Mar; 8(2):85-9. PubMed ID: 16507216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment.
    Rini BI; Shah SN
    Urology; 2010 May; 75(5):1114-5; author reply 1115. PubMed ID: 20451727
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment.
    Vaishampayan U
    Urology; 2010 May; 75(5):1114; author reply 1115. PubMed ID: 20451726
    [No Abstract]   [Full Text] [Related]  

  • 15. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Kondo T
    Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
    [No Abstract]   [Full Text] [Related]  

  • 16. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract]   [Full Text] [Related]  

  • 17. [Renal cell carcinoma].
    Oya M
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):29-31. PubMed ID: 20140991
    [No Abstract]   [Full Text] [Related]  

  • 18. Trials probe new agents for kidney cancer.
    Hampton T
    JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
    [No Abstract]   [Full Text] [Related]  

  • 19. [New therapeutic regimes in metastasic renal-cell carcinoma].
    Bierer S; Hertle L; Nitschmann S
    Internist (Berl); 2008 Jan; 49(1):114-7. PubMed ID: 18704353
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
    Shaheen PE; Rini BI; Bukowski RM
    Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.